Literature DB >> 28815553

Osteoporosis in patients with erythropoietic protoporphyria.

M Biewenga1, R H S Matawlie1, E C H Friesema1, H Koole-Lesuis1, M Langeveld1, J H P Wilson1, J G Langendonk1.   

Abstract

BACKGROUND: Erythropoietic protoporphyria (EPP) is a rare metabolic disease with painful photosensitivity due to protoporphyrin IX accumulation.
OBJECTIVES: To evaluate bone mineral density (BMD) and known osteoporosis risk factors in patients with EPP.
METHODS: Patients with EPP attending the Erasmus MC outpatient clinic who had undergone BMD measurements were included. Plasma 25 hydroxy (OH) vitamin D, alkaline phosphatase, parathyroid hormone and total protoporphyrin IX levels were measured; information on lifestyle, sunlight exposure and a bone-relevant physical exercise index [Bone Physical Activity Questionnaire (BPAQ) score] was obtained via questionnaires. BMD scores and the prevalence of osteopenia and osteoporosis in the EPP population were compared with a reference population.
RESULTS: Forty-four patients with EPP (23 female, 21 male; mean age 37·6 years) were included. The mean SDs of the T-scores were -1·12 for the lumbar spine and -0·82 for the femoral neck (both P < 0·001). Osteopenia was present in 36%; osteoporosis in 23%. Based on the reference population the expected prevalence was 15% and 1%, respectively. Prevalence of vitamin D deficiency was 50% (defined as a 25-OH vitamin D level < 50 nmol L-1 ). Mean self-reported BPAQ score was 19·4 units (reference interval 19-24). Multiple linear regression analysis showed a significant influence of vitamin D deficiency and bone-relevant physical exercise score on BMD in patients with EPP.
CONCLUSIONS: The prevalence of osteoporosis and osteopenia is greatly increased in patients with EPP. Alkaline phosphatase (related to vitamin D deficiency) and amount of weight-bearing exercise are significantly correlated with low BMD in this population.
© 2017 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28815553     DOI: 10.1111/bjd.15893

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  7 in total

1.  Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP.

Authors:  Michael Linenberger; Kleber Y Fertrin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 2.  Erythropoietic Protoporphyria and X-Linked Protoporphyria: pathophysiology, genetics, clinical manifestations, and management.

Authors:  Manisha Balwani
Journal:  Mol Genet Metab       Date:  2019-01-24       Impact factor: 4.797

Review 3.  Nutrients and Porphyria: An Intriguing Crosstalk.

Authors:  Elena Di Pierro; Francesca Granata
Journal:  Int J Mol Sci       Date:  2020-05-14       Impact factor: 5.923

4.  Diagnosis of erythropoietic protoporphyria with severe liver injury: A case report.

Authors:  Hui-Min Liu; Guo-Hong Deng; Qing Mao; Xiao-Hong Wang
Journal:  World J Gastroenterol       Date:  2019-02-21       Impact factor: 5.742

5.  Porphyria: What Is It and Who Should Be Evaluated?

Authors:  Yonatan Edel; Rivka Mamet
Journal:  Rambam Maimonides Med J       Date:  2018-04-19

Review 6.  Bone health in patients with inborn errors of metabolism.

Authors:  M Langeveld; C E M Hollak
Journal:  Rev Endocr Metab Disord       Date:  2018-03       Impact factor: 6.514

Review 7.  Recognized and Emerging Features of Erythropoietic and X-Linked Protoporphyria.

Authors:  Elena Di Pierro; Francesca Granata; Michele De Canio; Mariateresa Rossi; Andrea Ricci; Matteo Marcacci; Giacomo De Luca; Luisa Sarno; Luca Barbieri; Paolo Ventura; Giovanna Graziadei
Journal:  Diagnostics (Basel)       Date:  2022-01-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.